ArticleMolecular medicine reports2019
Escherichia coli promotes DSS‑induced murine colitis recovery through activation of the TLR4/NF‑κB signaling pathway.
Article in Molecular medicine reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 13 citations in OpenAlex.
- Rice bran extract ameliorates experimental colitis by modulating gut dysbiosis and toll-like receptor 4/nuclear factor kappa β signaling.Indian journal of pharmacology · 2026Article
- Optimization of dextran sulfate sodium-induced colitis and associated mortality in BALB/c mice.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas · 2026Article
- Dietary patterns and osteoporosis risk in a high-altitude population: the roles of gut microbiota and plasma metabolites in a case-control study.Frontiers in nutrition · 2026Article
- Exploring the etiology of colitis: insights from gut microbiota research.Gut microbes · 2025Review
- Research progress concerning the involvement of the intestinal microbiota in the occurrence and development of inflammatory bowel disease.World journal of gastroenterology · 2025Review
- Progress in targeting tumor-associated macrophages in cancer immunotherapy.Frontiers in immunology · 2025Review
- Priority order of neonatal colonization by a probiotic or pathogenicFrontiers in microbiology · 2024Article
- The beneficial effects of commensal E. coli for colon epithelial cell recovery are related with Formyl peptide receptor 2 (Fpr2) in epithelial cells.Gut pathogens · 2023Article
- Protective effect and mechanism insight of purified Antarctic kill phospholipids against mice ulcerative colitis combined with bioinformatics.Natural products and bioprospecting · 2023Article
- Role of adherent invasiveWorld journal of clinical cases · 2022Review
- Potential role of ovomucin and its peptides in modulation of intestinal health: A review.International journal of biological macromolecules · 2020Review
- Bacterial Immunogenicity Is Critical for the Induction of Regulatory B Cells in Suppressing Inflammatory Immune Responses.Frontiers in immunology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Increasing evidence suggests that intestinal microbiota have critical function in the pathogenesis of inflammatory bowel disease. This present study investigated the effects of Escherichia coli (E. coli) in mice with dextran sulfate sodium (DSS)‑induced colitis. Furthermore, Toll‑like receptor 4 (TLR4) and nuclear factor‑κB (NF‑κB) gene expression was measured by reverse transcription‑quantitative polymerase chain reaction. In total, two experiments were performed. In the first experiment, four groups were established in BALB/c mice: i) Group A, control (no treatments); ii) group B, DSS‑induced colitis; iii) group C, DSS‑induced colitis bacteria depleted (BD) mice; and iv) group D, E. coli‑treated DSS‑induced colitis BD mice. In the second experiment, there were three groups: i) Group A1, control C57BL/6 mice; ii) group B1, E. coli‑treated DSS‑induced colitis BD C57BL/6 mice; and iii) E. coli‑treated DSS‑induced colitis BD TLR4‑/‑ mice. Clinical outcomes, colon and immune histopathology and tissue myeloperoxidase activity were assessed. Mice with DSS‑induced colitis that were treated with E. coli exhibited enhanced recovery, with significantly improved clinical and histological scores compared with the DSS only group. The mRNA expression of TLR4 and NF‑κB in the E. coli‑treated group was also significantly higher. These effects were abolished in TLR4‑/‑ mice, suggesting that E. coli may have promoted recovery through the TLR4 pathway. The present study indicated that E. coli promoted recovery from DSS‑induced colitis in mice, potentially through activation of the TLR4/NF‑κB signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.